Free Trial
→ I'm handing you this one free (From Behind the Markets) (Ad)tc pixel
NASDAQ:XCUR

Exicure Q2 2026 Earnings Results & Report

Exicure logo
$1.06 -0.05 (-4.50%)
Closing price 03:59 PM Eastern
Extended Trading
$1.10 +0.04 (+3.40%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exicure beat analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$0.18 versus the -$18.60 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes

Exicure EPS Results

Actual EPS
-$0.18
Consensus EPS
-$18.60
Beat/Miss
Beat by +$18.42
One Year Ago EPS
N/A

Exicure Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.64 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Exicure's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

Exicure Q2 2026 Earnings FAQ

Exicure (NASDAQ:XCUR) reported earnings of -$0.18 per share for Q2 2026, beating the consensus estimate of -$18.60. The report was announced on Friday, August 14, 2026.

Exicure's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Exicure on the company's earnings history page.

Exicure Earnings Headlines

Exicure Inks $4.8M Asset Deal to Strengthen Balance Sheet
November 11 at 10:27 AM  |  benzinga.comhttps://www.benzinga.com/m-a/26/11/63144891/exicure-inks-4-8m-asset-deal-to-strengthen-balance-sheet?utm_source=snapi
Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
November 10 at 8:21 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/exicure-inc-announces-agreement-to-sell-gpc-100-program-assets-to-gpcrt-inc-for-krw-6-5-billion-1036744265
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
November 12 at 1:00 AM  |  Weiss Ratings (Ad)
Exicure Announces Agreement to Sell GPC-100 Program Assets to GPCRT for Approximately $4.8 Million
November 10 at 4:10 PM  |  quiverquant.comQ
Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
November 10 at 3:50 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/10/3400161/33289/en/exicure-inc-announces-agreement-to-sell-gpc-100-program-assets-to-gpcrt-inc-for-krw-6-5-billion.html
Exicure (XCUR) Projected to Announce Earnings on Thursday
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31180033
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR) is a biotechnology company that historically focused on developing therapeutics based on spherical nucleic acid (SNA) technology. The company’s platform was designed to use three-dimensional arrangements of nucleic acids to target specific genetic and biological pathways, with potential applications in diseases that are difficult to address using conventional drug-delivery approaches.

Exicure’s development programs included candidates for genetic and neurological disorders, as well as dermatological and other conditions. Its research portfolio has included programs aimed at Friedreich’s ataxia and other diseases involving abnormal gene expression. The company has also explored SNA-based treatments for skin and hair disorders and partnered with larger pharmaceutical companies on selected development efforts.

Exicure was founded in 2011 and was based in the Chicago, Illinois, area. Its programs were primarily directed toward the development of novel medicines rather than the sale of marketed products. Public disclosures in later years described significant operational and development challenges, and information about the company’s current activities and leadership is limited.

View Exicure Profile
Earnings Tools